2-chloromethyl-3,5,6-trimethyl-pyrazine hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-chloromethyl-3,5,6-trimethyl-pyrazine hydrochloride
• 英文别名: 2-Chloromethyl-3,5,6-trimethyl-pyrazine hydrochloride；2-(chloromethyl)-3,5,6-trimethylpyrazine;hydrochloride
• 化学式: C₈H₁₁ClN₂*ClH
• 分子量: 207.103
• InChiKey: LCIONGSMCVJCOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.56
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  25.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-chloromethyl-3,5,6-trimethyl-pyrazine hydrochloride 在 1-羟基苯并三唑 、 一水合肼 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 9.0h， 生成 2-hydroxy-N-((3,5,6-trimethylpyrazin-2-yl)methyl)benzamide
  参考文献：
  名称：

  川gust嗪衍生物。第8部分：设计，合成和初步鉴定作为心血管药物的新型川gust嗪酰胺。

  摘要：

  设计，合成和评价了一系列新的川gust嗪酰胺对损伤的血管内皮细胞的保护作用。初步结果表明，某些化合物在刺激受过氧化氢损伤的人脐带血管内皮细胞（HUVEC）复制方面具有比川gust嗪更强的活性。在活性化合物中，化合物8i，8t和8u表现出最高的效力，EC 3值分别为0.037、0.070和0.055mM。构效关系进行了简要讨论。

  DOI：

  10.2174/157340641130900042
• 作为产物：
  描述：

  川芎嗪 在 氯化亚砜 、 双氧水 、 乙酸酐 、 溶剂黄146 作用下， 以 二氯甲烷 为溶剂， 反应 2.5h， 生成 2-chloromethyl-3,5,6-trimethyl-pyrazine hydrochloride
  参考文献：
  名称：

  川gust嗪衍生物。第8部分：设计，合成和初步鉴定作为心血管药物的新型川gust嗪酰胺。

  摘要：

  设计，合成和评价了一系列新的川gust嗪酰胺对损伤的血管内皮细胞的保护作用。初步结果表明，某些化合物在刺激受过氧化氢损伤的人脐带血管内皮细胞（HUVEC）复制方面具有比川gust嗪更强的活性。在活性化合物中，化合物8i，8t和8u表现出最高的效力，EC 3值分别为0.037、0.070和0.055mM。构效关系进行了简要讨论。

  DOI：

  10.2174/157340641130900042

文献信息

• [EN] PYRROLIDINO HETEROCYCLES<br/>[FR] HÉTÉROCYCLES PYRROLIDINO
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013178569A1

  公开（公告）日：2013-12-05

  The invention relates to compounds of formula I wherein A1, A2, A3, B, R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as medicaments.

  这项发明涉及公式I的化合物，其中A1、A2、A3、B、R1、R2、R3和R4如描述和索赔中所定义，并且其生理上可接受的盐。这些化合物抑制PDE10A，可用作药物。
• PYRROLIDINO HETEROCYCLES
  申请人：HOFFMANN-LA ROCHE INC.

  公开号：US20150087644A1

  公开（公告）日：2015-03-26

  The invention relates to compounds of formula I wherein A 1 , A 2 , A 3 , B, R 1 , R 2 , R 3 and R 4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as medicaments.

  这项发明涉及公式I的化合物，其中A1、A2、A3、B、R1、R2、R3和R4如描述和索赔中所定义，并且其生理上可接受的盐。这些化合物抑制PDE10A并可用作药物。
• Design, synthesis, and biological activities of novel Ligustrazine derivatives
  作者：Xian-Chao Cheng、Xin-Yong Liu、Wen-Fang Xu、Xiu-Li Guo、Yang Ou

  DOI：10.1016/j.bmc.2007.03.033

  日期：2007.5

  A series of novel Ligustrazine derivatives was designed, synthesized, and assayed for their protective effects on damaged ECV-304 cells and antiplatelet aggregation activities. The results showed that most Ligustrazine derivatives exhibited lower EC50 values for protective effects on the ECV-304 cells damaged by hydrogen peroxide in comparison with Ligustrazine. And some Ligustrazine derivatives presented better antiplatelet aggregation activities than Ligustrazine. The derivatives containing the bisphenylmethyl pharmacophore (7a-c) exhibited highest potency. Compound 7a displayed most potential protective effects on the ECV-304 cells damaged by hydrogen peroxide, and compound 7c was found to be the most active antiplatelet aggregation agent. Structure-activity relationships were briefly discussed. (c) 2007 Elsevier Ltd. All rights reserved.
• Ligustrazine derivatives. Part 3: Design, synthesis and evaluation of novel acylpiperazinyl derivatives as potential cerebrocardiac vascular agents
  作者：Xian-Chao Cheng、Xin-Yong Liu、Wen-Fang Xu、Xiu-Li Guo、Ning Zhang、Yu-Ning Song

  DOI：10.1016/j.bmc.2009.03.012

  日期：2009.4

  A series of novel acylpiperazinyl Ligustrazine derivatives was designed, synthesized, and their protective effects on damaged ECV-304 cells and antiplatelet aggregation activities were evaluated. The results showed that compound E33 displayed most potential protective effects on the ECV-304 cells damaged by hydrogen peroxide, and compound E1 was found to be the most active antiplatelet aggregation agent. Structure-activity relationships were briefly discussed. (C) 2009 Elsevier Ltd. All rights reserved.
• Cheng, Xian-Chao; Liu, Xin-Yong; Xu, Wen-Fang, Journal of Chemical Research, 2006, # 9, p. 577 - 579
  作者：Cheng, Xian-Chao、Liu, Xin-Yong、Xu, Wen-Fang

  DOI：——

  日期：——